Pluri (PLUR) Competitors $4.39 +0.03 (+0.69%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$4.36 -0.02 (-0.57%) As of 03/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. VIRI, VXRT, EDIT, ELUT, RENB, TLSA, ADVM, COYA, CHRS, and MISTShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Virios Therapeutics (VIRI), Vaxart (VXRT), Editas Medicine (EDIT), Elutia (ELUT), Renovaro (RENB), Tiziana Life Sciences (TLSA), Adverum Biotechnologies (ADVM), Coya Therapeutics (COYA), Coherus BioSciences (CHRS), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Virios Therapeutics Vaxart Editas Medicine Elutia Renovaro Tiziana Life Sciences Adverum Biotechnologies Coya Therapeutics Coherus BioSciences Milestone Pharmaceuticals Pluri (NASDAQ:PLUR) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, community ranking, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Is PLUR or VIRI more profitable? Virios Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -3,551.49%. Virios Therapeutics' return on equity of -130.33% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-3,551.49% -2,778.13% -83.61% Virios Therapeutics N/A -130.33%-115.00% Which has more risk & volatility, PLUR or VIRI? Pluri has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Do institutionals and insiders hold more shares of PLUR or VIRI? 16.6% of Pluri shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 10.2% of Pluri shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in PLUR or VIRI? Virios Therapeutics received 3 more outperform votes than Pluri when rated by MarketBeat users. CompanyUnderperformOutperformPluriN/AN/AVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Which has better valuation & earnings, PLUR or VIRI? Virios Therapeutics has lower revenue, but higher earnings than Pluri. Virios Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$678K45.31-$20.89M-$5.60-0.78Virios TherapeuticsN/AN/A-$5.30M-$0.27-20.89 Do analysts rate PLUR or VIRI? Virios Therapeutics has a consensus price target of $3.00, indicating a potential downside of 46.81%. Given Virios Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Virios Therapeutics is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to PLUR or VIRI? In the previous week, Pluri had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Pluri and 1 mentions for Virios Therapeutics. Pluri's average media sentiment score of 1.44 beat Virios Therapeutics' score of 0.59 indicating that Pluri is being referred to more favorably in the media. Company Overall Sentiment Pluri Positive Virios Therapeutics Positive SummaryVirios Therapeutics beats Pluri on 9 of the 16 factors compared between the two stocks. Remove Ads Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.72M$3.03B$5.63B$7.84BDividend YieldN/A1.55%5.33%4.01%P/E Ratio-0.7830.4523.6018.74Price / Sales45.31431.82388.2390.77Price / CashN/A168.6838.1734.64Price / Book-10.453.926.894.23Net Income-$20.89M-$71.95M$3.20B$247.47M7 Day Performance-0.23%-5.68%-3.06%-2.29%1 Month Performance0.69%-12.09%1.52%-5.81%1 Year Performance-31.92%-27.90%9.37%-0.96% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri1.0134 of 5 stars$4.39+0.7%N/A-31.9%$30.72M$678,000.00-0.78150Short Interest ↓Positive NewsVIRIVirios Therapeutics0.3916 of 5 stars$6.33-7.3%$3.00-52.6%+1,077.2%$121.90MN/A-23.445News CoverageGap UpVXRTVaxart2.2044 of 5 stars$0.51-0.7%$4.00+680.3%-67.6%$116.61M$28.70M-1.25120Analyst ForecastAnalyst RevisionNews CoverageEDITEditas Medicine4.0729 of 5 stars$1.39+6.1%$6.83+391.6%-83.2%$115.34M$32.31M-0.54230Analyst RevisionELUTElutia3.9271 of 5 stars$2.81-3.8%$9.00+220.3%-16.2%$114.47M$24.38M-1.08180Short Interest ↓News CoveragePositive NewsRENBRenovaro1.0624 of 5 stars$0.72+2.6%N/A-78.1%$114.04MN/A-0.7720Positive NewsGap DownTLSATiziana Life Sciences0.4827 of 5 stars$1.08-2.7%N/A+146.7%$113.83MN/A0.008Short Interest ↑ADVMAdverum Biotechnologies4.4055 of 5 stars$5.40+5.9%$27.83+415.4%-67.4%$112.33M$1M-0.90190Insider TradeNews CoveragePositive NewsCOYACoya Therapeutics2.0354 of 5 stars$6.65-0.4%$17.00+155.6%-33.9%$111.22M$3.55M-10.236Analyst ForecastAnalyst RevisionNews CoverageCHRSCoherus BioSciences3.58 of 5 stars$0.95-7.6%$5.38+464.5%-64.9%$110.35M$266.96M-11.90330MISTMilestone Pharmaceuticals2.3114 of 5 stars$2.05+7.9%$17.00+729.3%-50.8%$109.38M$1M-2.5330Analyst ForecastNews CoverageGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Virios Therapeutics Competitors Vaxart Competitors Editas Medicine Competitors Elutia Competitors Renovaro Competitors Tiziana Life Sciences Competitors Adverum Biotechnologies Competitors Coya Therapeutics Competitors Coherus BioSciences Competitors Milestone Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLUR Stock Free PLUR Stock Alerts